NIH Research Reveals Why GLP-1 Weight Loss Drugs Plateau and How to Extend Their Effects
Scientists funded by the National Institutes of Health have discovered why GLP-1 based weight loss medications often reach a plateau over time. The research reveals that semaglutide, the active ingredient in Ozempic and Wegovy, triggers varying responses in the brain cells responsible for controlling appetite.
The findings offer insight into